Center for Global Research Data

Risk of recurrent venous thromboembolism and bleeding in cancer patients an individual patient data meta-analysis

Lead Investigator: Floris Bosch, University of Amsterdam Academic Medical Center
Title of Proposal Research: Risk of recurrent venous thromboembolism and bleeding in cancer patients an individual patient data meta-analysis
Vivli Data Request: 6471
Funding Source: None
Potential Conflicts of Interest: None

Summary of the Proposed Research:

Venous thromboembolism (VTE) is a frequent problem in patients with cancer. Over the last few years, with the introduction of direct oral anticoagulants (DOACs), more treatment options have emerged. However, regardless of type of anticoagulation, patients with cancer-associated VTE still have a high risk of recurrent thrombosis in the first 6 months. Furthermore, cancer patients treated with anticoagulation are at higher risk of bleeding compared to patients without cancer.

Decisions about the optimal intensity and duration of anticoagulant treatment could be guided by risk assessment tools, which assess the risk of recurrent VTE or bleeding in cancer patients. For example, such tools could be used to decide in which patients a dose reduction to 75% after on month should be avoided because of high risk of recurrent VTE. On the other hand, bleeding risk scores could aid in the decision making of treatment duration in patients with a high risk of bleeding. To date, no risk prediction scores for bleeding in cancer patients are developed. Therefore, the aim of this study is to derivate and validate a new prediction model for recurrent VTE and a risk prediction model for bleeding in cancer patients.

Requested Studies:

RANDOMIZED COMPARISON OF LOW MOLECULAR WEIGHT HEPARIN VERSUS ORAL WARFARIN THERAPY FOR LONG TERM ANTICOAGULATION IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM
Data Contributor: Pfizer Inc.
Study ID: A6301030

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial (CATCH trial)
Data Contributor: I WILL BRING MY OWN
Study ID: NCT01130025

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer (Caravaggio trial)
Data Contributor: I WILL BRING MY OWN
Study ID: NCT03045406

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Data Contributor: I WILL BRING MY OWN
Study ID: NCT02585713

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Data Contributor: I WILL BRING MY OWN
Study ID: NCT02583191

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism (Hokusai VTE Cancer trial)
Data Contributor: I WILL BRING MY OWN
Study ID: NCT02073682

The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial.
Data Contributor: I WILL BRING MY OWN
Study ID: NCT02744092